Penumbra Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Portfolio Pulse from Benzinga Insights
Penumbra (NYSE:PEN) has received 8 analyst ratings in the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is $281.5, with a recent decrease of 1.34%. Analyst actions include maintaining, raising, and lowering ratings and price targets. Penumbra develops medical devices, showing strong financial health with a revenue growth rate of 28.69%, a net margin of 19.05%, and an ROE of 4.75%. The company's financial strategy is highlighted by a low debt-to-equity ratio of 0.2.
March 22, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Penumbra has received mixed analyst ratings with a slight decrease in the average price target. The company's strong financial performance and low debt-to-equity ratio indicate a solid market position.
The mixed analyst ratings with a slight decrease in the average price target suggest a neutral short-term impact on Penumbra's stock price. However, the company's strong financial performance, including high revenue growth and net margin, alongside a low debt-to-equity ratio, positions it well in the market. These factors could counterbalance the negative sentiment from the lowered price targets, leading to a neutral short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100